These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34067716)

  • 1. Colistin Dosing Regimens against
    Nguyen VTK; Montakantikul P; Tragulpiankit P; Houngsaitong J; Shuib MF
    Antibiotics (Basel); 2021 May; 10(5):. PubMed ID: 34067716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and safety of colistimethate sodium in critical patients: an in vitro study by using of Monte Carlo simulation].
    Pan A; Mei Q; Yang T; Gao X; Lu H; Ye Y; Li J; Liu B
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 May; 29(5):385-389. PubMed ID: 28524024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
    Hang Y; Chen Y; Xue L; Sun S; Liu L; Gao J; Xie C; Zhang X; Zhu J; Jin J; Miao L
    Int J Antimicrob Agents; 2018 Mar; 51(3):484-487. PubMed ID: 28709989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colistin plus Sulbactam or Fosfomycin against Carbapenem-Resistant
    Saelim W; Changpradub D; Thunyaharn S; Juntanawiwat P; Nulsopapon P; Santimaleeworagun W
    Infect Chemother; 2021 Mar; 53(1):128-140. PubMed ID: 34409786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Evaluation of Meropenem Dosing Regimens Against ESBL-Producing
    Win EE; Htun KW; Tragulpiankit P; Tangtrakultham S; Montakantikul P
    Infect Drug Resist; 2022; 15():439-453. PubMed ID: 35177911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/Pharmacodynamic (PK/PD) Simulation for Dosage Optimization of Colistin Against Carbapenem-Resistant
    Jitaree K; Sathirakul K; Houngsaitong J; Asuphon O; Saelim W; Thamlikitkul V; Montakantikul P
    Antibiotics (Basel); 2019 Aug; 8(3):. PubMed ID: 31443514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetic Modeling Using Polymyxin B Free Plasma Concentrations From Published Reports and Evaluation of Dosage Regimens Based on Monte Carlo Simulation in Critically Ill Patients.
    Zheng Y; Xu B; Chen S; Liu M; Huang H; Wang J; Wu X
    J Clin Pharmacol; 2023 Sep; 63(9):1036-1044. PubMed ID: 37125471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using Monte Carlo simulation.
    Wang G; Yu W; Cui Y; Shi Q; Huang C; Xiao Y
    BMC Infect Dis; 2021 Mar; 21(1):307. PubMed ID: 33771113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Intravenous Fosfomycin Disodium Dosing Regimens in Critically Ill Patients for Treatment of Carbapenem-Resistant Enterobacterales Infections Using Monte Carlo Simulation.
    Leelawattanachai P; Wattanavijitkul T; Paiboonvong T; Plongla R; Chatsuwan T; Usayaporn S; Nosoongnoen W; Montakantikul P
    Antibiotics (Basel); 2020 Sep; 9(9):. PubMed ID: 32961833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant
    Kanchanasurakit S; Santimaleeworagun W; McPherson CE; Piriyachananusorn N; Boonsong B; Katwilat P; Saokaew S
    Infect Chemother; 2020 Dec; 52(4):516-529. PubMed ID: 33124216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation.
    Asuphon O; Montakantikul P; Houngsaitong J; Kiratisin P; Sonthisombat P
    Int J Infect Dis; 2016 Sep; 50():23-9. PubMed ID: 27418581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of colistin dosing regimen for cystic fibrosis patients with chronic Pseudomonas aeruginosa biofilm lung infections.
    Hengzhuang W; Green K; Pressler T; Skov M; Katzenstein TL; Wu X; Høiby N
    Pediatr Pulmonol; 2019 May; 54(5):575-580. PubMed ID: 30803159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease.
    Xiao AJ; Caro L; Popejoy MW; Huntington JA; Kullar R
    Infect Dis Ther; 2017 Mar; 6(1):137-148. PubMed ID: 28013453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Lewis SJ; Kays MB; Mueller BA
    J Clin Pharmacol; 2016 Oct; 56(10):1277-87. PubMed ID: 26919659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients.
    Xie YL; Jin X; Yan SS; Wu CF; Xiang BX; Wang H; Liang W; Yang BC; Xiao XF; Li ZL; Pei Q; Zuo XC; Peng Y
    Front Pharmacol; 2022; 13():967412. PubMed ID: 36105229
    [No Abstract]   [Full Text] [Related]  

  • 16. Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study.
    Chaijamorn W; Charoensareerat T; Srisawat N; Pattharachayakul S; Boonpeng A
    J Intensive Care; 2018; 6():61. PubMed ID: 30221005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical.
    Sorlí L; Luque S; Li J; Campillo N; Danés M; Montero M; Segura C; Grau S; Horcajada JP
    J Infect; 2019 Sep; 79(3):253-261. PubMed ID: 31265867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring colistin pharmacodynamics against Klebsiella pneumoniae: a need to revise current susceptibility breakpoints.
    Tsala M; Vourli S; Georgiou PC; Pournaras S; Tsakris A; Daikos GL; Mouton JW; Meletiadis J
    J Antimicrob Chemother; 2018 Apr; 73(4):953-961. PubMed ID: 29377998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics of Colistin Sulfate in Critically Ill Patients: Exposure and Clinical Efficacy.
    Yu XB; Zhang XS; Wang YX; Wang YZ; Zhou HM; Xu FM; Yu JH; Zhang LW; Dai Y; Zhou ZY; Zhang CH; Lin GY; Pan JY
    Front Pharmacol; 2022; 13():915958. PubMed ID: 35784679
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.